FDA ADVISORY COMMITTEES Mary A Foulkes, Ph.D. Office of Biostatistics and Epidemiology Center for Biologics Evaluation and Research, FDA FDA/Industry.

Slides:

Advertisements

Similar presentations

Discussion: Biostatistics in Public Policy

Advertisements

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.

1 GOOD MORNING! BONJOUR! GOEDEMORGEN!. 2 An Introduction to certain aspects of the US FDA Murray M. Lumpkin, MD Deputy Commissioner International Programs.

Advisory Committees Linda Ann Sherman, MD, MPA Advisory Committee Oversight and Management Staff, Director U.S. Food and Drug Administration April 20,

Advancing the Development of Pediatric Therapeutics II: Evaluation of Long-term Neurocognitive Development in Pediatrics Lynne P. Yao, M.D. Acting Director,

Role of the Executive Secretary Gail Dapolito Advisory Committee Coordinator Div. Scientific Advisors and Consultants Center for Biologics Evaluation and.

Risk Communication Advisory Committee Risk Communication Issues in the Food and Drug Administration Amendments Act of 2007 February 28, 2008.

FDA Advisory Committees: A Unique Element of our Decision-Making Process Murray M. Lumpkin, M.D. Acting Deputy Commissioner International and Special Programs.

FDA and Communication about Regulated Products Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee August.

Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.

History of FDA and Related Regulatory Agencies

Oncologic Drugs Advisory Committee September 6, 2006 ODAC and the FDA Arms-Length or Arm-In-Arm? Abigail Alliance for Better Access to Developmental Drugs.

Clinical and Surrogate Endpoints for Evaluating Efficacy of Alpha 1 - Proteinase Inhibitor (Human) Augmentation Therapy Topic II - Introduction Blood Products.

Introduction to Regulation

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.

Special Topics in IND Regulation

Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.

1 Advisory Committee Member Training Louis R. Cantilena, Jr., M.D., Ph.D. Former Chair, Nonprescription Drug Advisory Committee Professor of Medicine and.

FDA’s Pharmaceutical Inspectorate Robert Coleman National Expert Drug Investigator Food and Drug Administration.

The FDA Landscape AdvaMed September 2008 Judith K. Meritz

Assessing the Impact of a Toll-Free Number for Reporting Side Effects in Direct-to-Consumer Television Ads: Proposed Study Design Kathryn J. Aikin, Ph.D.

The Role of Chemists in the FDA Drug Approval Process 231 st ACS National Meeting Atlanta, GA M. Scott Furness, Ph.D. March 26, 2006.

FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.

Commissioner Appraisals A Self Appraisal. What is Self-Assessment Relationship with board members Relationship with ED and staff Relationship with performance.

Physiologists & the FDA Kevin J. Greenlees, Ph.D., DABT Senior Advisor for Science & Policy Office of New Animal Drug Evaluation FDA Center for Veterinary.

1 FDA Regulation of Cell Therapy Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies Fourth Annual Translational Stem.

FDA Science Board Drug Safety Initiative April 15, 2005 Rockville, MD RADM Steven Galson, MD, MPH Acting Director, Center for Drug Evaluation and Research.

Counter-terrorism at FDA Andrea Meyerhoff MD Director, Office of Counter-terrorism US Food and Drug Administration.

1 FDA/CDRH Office of In Vitro Diagnostic Devices The Pre-IDE Process Sousan S. Altaie, Ph.D. Scientific Policy Advisor OIVD.

PATRICIA KERBY, MPA HUMAN SUBJECTIONS PROTECTION COMPLIANCE OFFICER OFFICE OF RESEARCH COMPLIANCE What are the FDA’s expectations in 2010?

Research Peer-Review at CDER Past and Present Jerry M. Collins, Ph.D. Director, Laboratory of Clinical Pharmacology, OTR Acting Director, Division of Applied.

NOAA Science Advisory Board …advises the Secretary of Commerce for Oceans and Atmosphere on long- and short- range strategies for research, education,

Secretary’s Workshop Standard Duties. Usually, the secretary position is the training ground for a future leadership position The standard duties of a.

Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.

PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE PCORI Board of Governors Meeting Washington, DC September 24, 2012 Anne Beal, MD, MPH, Chief Operating Officer.

History of Pediatric Labeling

1 Nonprescription Drugs AC Meeting March 23, 2005 Efficacy of OTC Healthcare Antiseptics: Introduction to the Regulatory Issues Susan S. Johnson, Pharm.D.,

Module C FDA Regulations Regulatory Documents Patricia E. Koziol 1Module C Final Version 10-apr-2010.

Chief, Gene Therapy Branch

FDA Science Board CDER Drug Safety Update November 6, 2005 Rockville, MD Steven Galson, MD, MPH Director, Center for Drug Evaluation and Research Food.

Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.

1 Drug Safety Oversight Board: Recent Activities FDA Science Board Advisory Committee Meeting March 31 st, 2006 Douglas C. Throckmorton, MD Deputy Director.

Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,

October 28, F OOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 (FDAAA) and Risk Evaluation and Mitigation Strategies (REMS) Presented to the Ninth.

1 Estimating CDER Resources Devoted to Safety Theresa M. Mullin, Ph.D. Office of Planning, Office of Commissioner April 15, 2005 Presentation to: FDA Science.

Preparation for FDA Advisory Committee Meetings Robert M. Kirsch, RAC Vice President, Regulatory Affairs TolerRx Inc. Cambridge, MA.

Title Page Quality Mo Samimi, Ph.D. CMQ/OE Presented at the ASQ Biomedical Division Northern California Discussion Group. May 2011.

FDA Risk Communication Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee February 28, 2008.

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

Functional Vision Endpoints: OCTGT Perspective Samuel B. Barone, M.D. Office of Cellular, Tissue, and Gene Therapies Center for Biologics Evaluation and.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.

Clinical Trial Design and other Statistical Issues Mary A. Foulkes, Ph.D. Office of Biostatistics and Epidemiology Vaccines and Related Biological Products.

1 Lotronex ® (alosetron HCl) Tablets Introduction Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products April.

FDA’s Patient Advocacy Programs: Patient Representative Program & Patient Network Andrea Furia-Helms, MPH James Valentine, MHS Office of Special Health.

Veterinary Products Management and Quality Control System in Thailand : Veterinary Vaccine Tasanee Lorchaivej Workshop on the Veterinary Products.

Guidance Development Merton V. Smith, Ph.D., J.D. Director International Programs and Product Standards Center for Veterinary Medicine, FDA.

Nonclinical Studies Subcommittee John Doull, M.D., Ph.D., Chair Advisory Committee for Pharmaceutical Science November 15, 2000.

Who Are We? A Forum of Stakeholders Who Come together to Develop Science-based Solutions.

ISO/HL Specification: Individual Case Safety Report (ICSR) Release 2 Lise Stevens Data Standards Project Manager FDA CBER/ADRM Bioinformatics Support.

My Experiences as an FDA Statistician

Clinical Review Process for New Drug Development and Application

נמטוציטים משושנת ים Eli. S Lec. No.2.

Clinical Trials — A Closer Look

FDA Perspective on Cardiovascular Device Development

Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.

American Society for Quality Region 5 Quality Conference

Bozeman Health Clinical Research

Visualization Using Open-Source Tools: some FDA perspectives

FDA Sentinel Initiative

Presentation transcript:

FDA ADVISORY COMMITTEES Mary A Foulkes, Ph.D. Office of Biostatistics and Epidemiology Center for Biologics Evaluation and Research, FDA FDA/Industry workshop Bethesda, MD September 19, 2003

Range of Advisory Committees CDER Cardio-Renal Drugs AntiInfective Drugs Antiviral Drugs Oncologic Drugs CBER Blood & Blood Products Vaccines CVM Veterinary Meds CDRH Circulatory System Devices Dental Devices Radiologic Devices CFSAN Food Advisory NCTR Ranch Hand

FACA Federal Advisory Committee Act Public Law Independent advice on scientific issues Enhance, compliment, speed decision- making Provide forum for public input (advanced notice, public meetings) nnel.jsp?channelId=-13689http:// nnel.jsp?channelId=-13689

FACA Scientific – Not Policy Advisory Only One hour for public comment Have Background material fr all sides 18 days prior to mtg (also webposted) Limitations on Last-Minute Material

INDEPENDENCE Appointed by Commissioner Fixed Terms Screened for COI/Bias Large Role Played by Chair

COMPOSITION Standing mbrs Scientific/Tech experts Statistician Consumer rep Industry rep Other invitees Patient rep Disease/condition experts Occasional Senators

Pre-Meeting IAs Generally Limited – Discussion of Issues must be in public Factual questions possible, but Exec Sec must be involved

FDA Reviewer General Public Executive Secretary Committee Member Industry

TYPICAL AGENDA 8:00 am 8:15 8:30 10:00 10:15 11:45 1:00 pm 2:00 4:30 Administrative remarks FDA Introduction Sponsor’s Presentation Break FDA’s Presentation Lunch Open Public Hearing Committee Disc’n & Vote Adjourn

Questions to ACs Were studies adequate to evaluate product effect? Was population studied appropriate? Is it appropriate to pool data? Optimal correction methodology for QT correction? Add’l pt safety monitoring advised? If licensed, should the label describe any limitations in generalizing to certain subgroups?

Issues for ACs Discuss trial designs, incl f/up dur’n Endpoints, esp surrogates Measurement/quant’n (e.g. QT interval & mult correction meths) Phase IV commitments 1 st year safety reviews of ped experience mandated by Best Pharmaceuticals for Children Act Generalizability of results

Perogative ACs can reword or answer the question they wish had been asked ACs often answer questions that were not asked, offering advice on future considerations ACs often ask for more information, more data (e.g. cross-resistance), more studies (e.g. Phase IV)

Statistician’s Responsibility Know their subject Know the process COMMUNICATE